GLP-1 Agonists for Obesity

JAMA. 2024 Aug 27;332(8):673. doi: 10.1001/jama.2024.12074.

Authors

Alyssa J Moran¹, Christina A Roberto²

Affiliations

¹ Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
² Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

PMID: 39083284
DOI: 10.1001/jama.2024.12074

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anti-Obesity Agents* / administration & dosage
Anti-Obesity Agents* / adverse effects
Diet, Healthy
Food Assistance*
Glucagon-Like Peptide-1 Receptor Agonists / administration & dosage
Glucagon-Like Peptide-1 Receptor Agonists / adverse effects
Humans
Obesity* / diet therapy
Obesity* / drug therapy
Weight Loss / drug effects

Substances

Anti-Obesity Agents
Glucagon-Like Peptide-1 Receptor Agonists